S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial
Masatoshi Kudo(Kindai University), Takuji Okusaka(National Cancer Centre Japan), Yozo Sato(Aichi Cancer Center), Masafumi Ikeda(National Cancer Center Hospital East), Xuemin Fang(Kitasato University), Kazushi Numata(Yokohama City University Medical Center), Yoshito Date(Keio University), Junji Furuse(Kanagawa Prefectural Hospital Organization), Shuichi Kaneko(Kanazawa University), Masahiro Takeuchi(The University of Tokyo), Hironori Tanaka(Hyogo Medical University), Seiji Kawazoe(Saga-Ken Medical Centre Koseikan), Shinichi Ohkawa(National Cancer Center Hospital East), Michihisa Moriguchi(Kyoto Prefectural University of Medicine), Madoka Takeuchi(Keio University), Hisashi Hidaka(Kitasato University)
Cited by 60
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k